Physician profile
Thomas Geppert
NPI 1174522874
$2,567.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $265 · 2021: $567.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.99 | 2019-2021 | |
| Amgen INC. | $375.19 | 2019-2021 | |
| Pfizer INC. | $310.16 | 2019-2021 | |
| Lilly USA, LLC | $258.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $176.48 | 2019-2021 | |
| Horizon Therapeutics Plc | $164.43 | 2019-2021 | |
| Radius Health, INC. | $136.70 | 2019 | |
| Janssen Biotech, INC. | $136.69 | 2019-2021 | |
| Genentech USA, INC. | $133.11 | 2019-2021 | |
| Ucb, INC. | $101.12 | 2019 | |
| Glaxosmithkline, LLC. | $72.69 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $72.61 | 2019-2021 | |
| Genzyme Corporation | $66.56 | 2019-2020 | |
| Celgene Corporation | $48.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.20 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $16.67 | 2019 | |
| Hikma Pharmaceuticals USA | $15.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.87 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Geppert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.